Keep up-to-date with BMS Canada
Montreal and Toronto, April 16, 2015
HEPATITIS C CURE RATE OF 97 PER CENT ANNOUNCED IN STUDY OF PATIENTS CO-INFECTED WITH HIV GIVEN 12-WEEK COMBINATION TREATMENT OF DACLATASVIR AND SOFOSBUVIR IN ALLY-2 TRIALPatient population with both infections historically challenging to treat due to drug-drug interactions.
Categories: Hepatitis C
Kirkland, QC – November 26, 2014
Expanded Access Programs
Expanded Access, Named Patient and Emergency Use Programs for Bristol-Myers Squibb Medicines. Find out more.
Events & Programs
BMS Canada is committed to community involvement. Find out more.
Looking for a Great Career?
Bristol-Myers Squibb Canada can offer you the challenge and support you are looking for in a friendly, motivating and exciting atmosphere. Find out more.